Pixatimod is under clinical development by Zucero Therapeutics and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas. According to GlobalData, Phase I drugs for Metastatic Adenocarcinoma of The Pancreas have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Pixatimod’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pixatimod (PG-545) is under development for the treatment of advanced solid tumors including microsatelite stable metastatic colorectal cancer, non-small cell lung cancer, metastatic colorectal cancer and melanoma, metastatic pancreatic cancer, metastatic adenocarcinoma of the pancreas, dengue and coronavirus disease 2019. It is administered through intravenous and subcutaneous (as a lyophilized powder) routes. It is a small molecule heparin sulfate mimetic. The drug candidate acts by targeting heparanase enzyme, VEGF, FGF-1, FGF-2, and TLR9 (toll-like receptor 9). It was also under development for the treatment of solid tumors (subcutaneous route).
Zucero Therapeutics overview
Zucero Therapeutics formerly Zucero Therapeutics Pty Ltd is a biotechnology company, which strives to discover and develop modified sugar compounds for the treatment of cancer. Its pipeline product candidate, PG545 (pixatimod, pINN), a new immunomodulatory agent, stimulates myeloid cells (M1 macrophages and dendritic cells (DC)). Initially, it stimulates the DC, leading to the activation of natural killer (NK) cells that are capable of destroying lymphomas. Next, it blocks tumour-associated macrophages (TAMs), in mouse models, which causes the inhibition of heparanase. PG545 completed a phase Ia clinical trial as a monotherapy in solid tumors and other inflammatory conditions. The company has research office in Darra, Queensland, Australia. Zucero Therapeutics is headquartered in Geelong, Victoria, Australia.
For a complete picture of Pixatimod’s drug-specific PTSR and LoA scores, buy the report here.